Royalty Pharma raises 2026 revenue forecast after Q2 receipts grow 6% to $773M

Royalty Pharma reported a 6% increase in Portfolio Receipts to $773 million in Q2 2026, driven by a 14% rise in Royalty Receipts from key drugs like Tremfya and Evrysdi. The company acquired new royalty interests, including AstraZeneca’s cliramitug, expanding its development pipeline to 19 therapies. Strong financial results led Royalty Pharma to raise its full-year 2026 Portfolio Receipts guidance to $3.4-$3.5 billion, reflecting continued growth and robust capital deployment exceeding $1 billion. This positions Royalty Pharma well for sustained growth in the biopharmaceutical royalty market.